Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas

Younes, Anas; Bartlett, Nancy L.; Leonard, John P.; Kennedy, Dallas C.; Lynch, Carmel M.; Sievers, Eric L.; Forero‐Torres, Andres

doi:10.1056/nejmoa1002965

Cited by 1,226 publications

(865 citation statements)

References 32 publications

(22 reference statements)

Supporting

Mentioning

827

Contrasting

Unclassified

Order By: Relevance

“…Some of the new agents for peripheral T-cell lymphomas are also expected to be effective for ENKL. Considering that 72 % of ENKLs are positive for CD30 [73], one of the most promising candidates is brentuximab vedotin, i.e., the CD30-specific monoclonal antibody conjugated to an anti-tubulin agent (monomethyl auristatin E) [74]. In any case, the efficacy of a new therapeutic strategy for ENKL should be evaluated by prospective clinical trials with adequate statistical considerations, as in the cases of other aggressive lymphomas.…”

Section: For the Better Future Management Of Enklmentioning

confidence: 99%

Current and future management of NK/T-cell lymphoma based on clinical trials

Yamaguchi

2012

Int J Hematol

View full text Add to dashboard Cite

Recently reported results of well-designed prospective clinical trials for extranodal NK/T-cell lymphoma, nasal type (ENKL) have rapidly changed the management of ENKL. This review will focus on the evidence obtained from prospective clinical trials for ENKL and discuss the most highly recommended current management and future directions for the better management of ENKL. For patients with nasal NK/T-cell lymphoma of stage IE or contiguous stage IIE with cervical node involvement, concurrent chemoradiotherapy with radiotherapy (RT) and a two-thirds dose of DeVIC chemotherapy is recommended as a first-line treatment. To obtain the expected clinical outcome, performing RT following the same procedure as that reported is important. For the other patients with newly diagnosed ENKL, SMILE chemotherapy is recommended as an induction therapy. The Epstein-Barr virus DNA load in peripheral blood is useful for both prognostication and monitoring during the follow-up after treatment. Other L-asparaginasecontaining chemotherapies and chemotherapies containing non-multidrug resistance-related agents and etoposide are good options for elderly patients or patients with impaired organ function. As in the cases of other aggressive lymphomas, prospective clinical trials with adequate statistical considerations should be conducted to improve the prognosis of patients with ENKL.

show abstract

Section: For the Better Future Management Of Enklmentioning

confidence: 99%

Current and future management of NK/T-cell lymphoma based on clinical trials

Yamaguchi

2012

Int J Hematol

View full text Add to dashboard Cite

show abstract

“…The antibody binds to CD30 and is internalized releasing the MMAE toxin, which inhibits proliferation and subsequently induces apoptosis of the malignant cell [19,20]. An initial phase 1 clinical trial in patients with Hodgkin lymphoma and anaplastic large cell lymphoma tested the administration of brentuximab vedotin every three weeks [21]. In this study, 17 of 45 patients had a response to the drug and 11 patients had a complete response.…”

Section: Brentuximab Vedotinmentioning

confidence: 99%

Hodgkin lymphoma: MOPP chemotherapy to PD‐1 blockade and beyond

Ansell

2015

American J Hematol

View full text Add to dashboard Cite

Hodgkin lymphoma is a rare lymphoid malignancy affecting~9,200 new patients in the United States annually. Progress in the management of this disease over the past 50 years has been remarkable and the prognosis of this malignancy has changed from a uniformly fatal process to one in which the vast majority of patients are expected to be cured. This remarkable progress has been due to the use of combination approaches incorporating chemotherapy and radiation therapy, and now more recently antibody-drug conjugates and immune checkpoint inhibitors. The goal for the future is to develop treatment combinations that successfully treat all patients and markedly decrease the long-term side effects.

show abstract

“…In fact, although it is obvious that it is less aggressive than the ALK -form, its course is nevertheless quite variable, being influenced by several factors: the age of the patient, the International Prognostic Index (IPI; a clinical tool developed to aid in predicting the prognosis of patients with aggressive non-Hodgkin lymphoma, and based on age, disease stage, serum lactic dehydrogenase (LDH), performance status, and presence of extranodal disease) and the state of the bone marrow. In addition, the prognosis of ALK + ALCL may soon be improved by the recent introduction of ALK inhibitors and SGN-35 in the clinical practice (67,68).…”

Section: Prognosismentioning

confidence: 99%

“…Conversely, CD30 is theoretically an optimal target for therapy owing to its minimal expression on nonmalignant cells, although the unconjugated anti-CD30 agents SGN-30 and MDX-060 demonstrated minimal effects in Hodgkin lymphoma and ALCL (93,94). However, more recently, in order to enhance the antitumor activity, the antitubulin agent monomethyl auristatin E (MMAE) was attached to a CD30-specific mAb by an enzyme-cleavable linker, producing the antibody-drug conjugate brentuximab vedotin (SGN-35) (95). Notably, this drug induced remarkable clinical responses in all relapsed/refractory CD30 + lymphomas with acceptable toxicity, leading to its rapid approval by FDA in this setting (95).…”

Section: Mabs Directed Against Surface Antigensmentioning

confidence: 99%

“…However, more recently, in order to enhance the antitumor activity, the antitubulin agent monomethyl auristatin E (MMAE) was attached to a CD30-specific mAb by an enzyme-cleavable linker, producing the antibody-drug conjugate brentuximab vedotin (SGN-35) (95). Notably, this drug induced remarkable clinical responses in all relapsed/refractory CD30 + lymphomas with acceptable toxicity, leading to its rapid approval by FDA in this setting (95). PTCLs are relatively rare tumors; however, they account for a substantial number of deaths worldwide.…”

Section: Mabs Directed Against Surface Antigensmentioning

confidence: 99%

See 1 more Smart Citation

New molecular insights into peripheral T cell lymphomas

Pileri

Piccaluga

2012

J. Clin. Invest.

View full text Add to dashboard Cite

Peripheral T cell lymphomas (PTCLs) are heterogeneous neoplasms and represent about 12% of all lymphoid malignancies. They are often regarded as "orphan diseases," a designation that does not reflect their real incidence but rather signifies the difficulties encountered in their classification, diagnosis, and treatment. Here we revise the current understanding of the pathobiological characteristics of the most common nodal PTCLs by focusing on the contribution given by high-throughput technologies and the identification of potential therapeutic targets proposed by translational studies.

show abstract

Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas

Cited by 1,226 publications

References 32 publications

Current and future management of NK/T-cell lymphoma based on clinical trials

Current and future management of NK/T-cell lymphoma based on clinical trials

Hodgkin lymphoma: MOPP chemotherapy to PD‐1 blockade and beyond

New molecular insights into peripheral T cell lymphomas

Contact Info

Product

Resources

About